Panacea Acquisition Quote - NUVB

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.43

Bid

Offer

Volume

387,741

3.43 Day's Range 3.50

0.95 52 Week Range 4.1598

Market Cap

850.267M

Previous Close

3.44

Open

3.49

Last Trade

3.44

Last Trade Time

01:18:31

Financial Volume

US$ 1,344,887

VWAP

3.4685

Average Volume (3m)

1,613,491

Shares Outstanding

247,170,648

Dividend Yield

PE Ratio

-11.28

Earnings Per Share (EPS)

-0.31

Revenue

Net Profit

-75.8M

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ecor1cap.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Panacea Acquisition Corp is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker NUVB. The last closing price for Panacea Acquisition was US$3.44. Over the last year, Panacea Acquisition shares have traded in a share price range of US$ 0.95 to US$ 4.1598.

Panacea Acquisition currently has 247,170,648 shares in issue. The market capitalisation of Panacea Acquisition is US$850.27 million. Panacea Acquisition has a price to earnings ratio (PE ratio) of -11.28.

Form PRER14A - Preliminary Proxy Soliciting materials

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.33	10.6451612903	3.1	3.57	3.01	1734003	3.31799393	CS
4	0.53	18.275862069	2.9	3.57	2.84	2232606	3.06891715	CS
12	0.71	26.1029411765	2.72	3.57	2.525	1613491	3.05907371	CS
26	1.79	109.146341463	1.64	4.1598	1.43	1418723	2.89285427	CS
52	1.72	100.584795322	1.71	4.1598	0.95	1216877	2.23418901	CS
156	-5.14	-59.9766627771	8.57	10.45	0.95	929488	3.64918643	CS
260	-6.57	-65.7	10	15.23	0.95	930591	4.6474955	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
1MCMorella Corporation Ltd	AUD 0.049 (1,533.33%)	158.83k
MSGMCS Services Limited	AUD 0.005 (400.00%)	26.31M
OSXOOsteopore Limited	AUD 0.007 (250.00%)	257.33k
DGRDGR Global Limited	AUD 0.03 (233.33%)	46.76M
LBTOALBT Innovations	AUD 0.009 (125.00%)	300k
VPRVolt Group Ltd	AUD 0.001 (-50.00%)	1.01M
1TTThrive Tribe Technologies Ltd	AUD 0.002 (-33.33%)	8.15M
ARVOCArtemis Resources Limited	AUD 0.002 (-33.33%)	4.92M
SIHSihayo Gold Limited	AUD 0.002 (-33.33%)	208k
SHOSportshero Limited	AUD 0.005 (-28.57%)	3.08M
DRODroneShield Limited	AUD 1.995 (-22.67%)	57.82M
NGSNutritional Growth Solutions Ltd	AUD 0.004 (33.33%)	54.75M
LSRLodestar Minerals Limited	AUD 0.001 (0.00%)	53.43M
DGRDGR Global Limited	AUD 0.03 (233.33%)	46.76M
OSXOsteopore Limited	AUD 0.065 (18.18%)	33.47M